EHA 2025: Nordic AML Group Explores Optimized Regimen for AML Patients

The combination of venetoclax (VEN) and azacytidine (AZA) has become the standard of care for newly diagnosed AML patients who are not candidates for intensive chemotherapy. However, this regimen is often associated with significant myelosuppression.
In this MEDtalk, Anne Louise Tølbøll Sørensen presents findings from a Nordic phase 2, prospective, multicenter trial evaluating the efficacy and safety of a reduced-duration venetoclax regimen. The study aims to optimize treatment by minimizing toxicity while maintaining therapeutic effect.